SynthesisBMC psychiatry2026
Digital phenotyping for predicting relapse in psychiatric disorders: a systematic review of passive sensing approaches.
Synthesis in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDigital phenotyping - the moment-by-moment quantification of individual-level human behavior using data from personal digital devices - offers a novel approach to continuous, passive monitoring of psychiatric patients. Changes in behavioral digital phenotypes may serve as early warning signs of relapse or clinical deterioration, creating an opportunity for timely preventive intervention.
methodsA systematic search of PubMed, PsycINFO, and IEEE Xplore was conducted for studies published up to January 2026. We included prospective and retrospective observational studies using passively collected smartphone or wearable data to predict relapse or clinical deterioration in individuals with diagnosed psychiatric disorders, with reported quantitative model performance metrics. Study quality was assessed using the modified Newcastle-Ottawa Scale [16] and the PROBAST [25, 26] tool. Data were synthesized narratively in accordance with the SWiM guideline.
resultsFifty-two studies encompassing 4,814 participants met inclusion criteria. Disorders studied included schizophrenia spectrum disorders (35%), bipolar disorder (27%), and major depressive disorder (23%). Key predictive features included alterations in sleep patterns (83% of studies), physical activity (83%), GPS-derived mobility (75%), and social communication frequency (65%). Machine learning models reported AUC values ranging from 0.70 to 0.88 for predicting relapse one to four weeks in advance, although the majority of these estimates were derived from internal validation and are likely to overestimate real-world performance. Multi-modal data integration and individual-level modeling consistently outperformed single-modality and population-level approaches. High risk of bias was identified in 75% of studies, primarily attributable to inadequate analytic methodology and reliance on internal validation.
conclusionsPassive digital phenotyping demonstrates significant promise for predicting psychiatric relapse across diagnostic categories, with moderate-to-good predictive discrimination (AUC 0.70-0.88) achievable up to four weeks prior to confirmed relapse. However, substantial methodological limitations - including reliance on internal validation, heterogeneous outcome definitions, and limited demographic diversity - must be addressed. Standardized outcome definitions, prospective external validation in diverse cohorts, and closed-loop intervention trials are required before widespread clinical implementation can be responsibly pursued.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.